Strides Arcolab is currently trading at Rs. 481.00, up by 73.65 points or 18.08% from its previous closing of Rs. 407.35 on the BSE.
The scrip opened at Rs. 410.90 and has touched a high and low of Rs. 488.80 and 407.00 respectively. So far 459047 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 488.80 on 24-Jan-2012 and a 52 week low of Rs. 276.25 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs. 488.80 and Rs. 377.05 respectively. The current market cap of the company is Rs. 2459.26 crore.
The promoters holding in the company stood at 28.42% while Institutions and Non-Institutions held 54.49% and 17.09% respectively.
Strides Arcolab, the Indian drug maker has sold its 94% stake in Ascent Pharmahealth, its subsidiary with operations in Australia and Southeast Asia, to Watson Pharmaceuticals, Inc. As part of the transaction, Watson also acquired the remaining 6% shareholding associated with Dennis Bastas, CEO of Ascent. The transaction was signed and closed simultaneously. The cash offer from Watson values Ascent at an enterprise value of Aus $375 million.
Ascent is a top five genetic pharmaceutical company in Australia and is present across several countries in Southeast Asia, including Singapore where it is the leading generic pharmaceutical company.
Watson is an integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women’s Health.
Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterlite injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1814.55 |
| Dr. Reddys Lab | 1350.60 |
| Cipla | 1478.95 |
| Lupin | 2172.15 |
| Zydus Lifesciences | 975.50 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
